Geneva, July 14 -- International Clinical Trials Registry received information related to the study (ACTRN12625000685415) titled 'Part B & Part D: Phase I Single and Multiple-Ascending Dose Trial of SPT-320 in Healthy Participants' on June 27.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Randomised controlled trial
Primary Sponsor: Seaport Therapeutics Australia Pty Ltd
Condition:
Anxiety
Anxiety
Mental Health - Anxiety
Intervention:
This study evaluates the safety, tolerability, pharmacokinetics (PK), and preliminary pharmacodynamics of SPT-320 and agomelatine following single dose in healthy adult participants.
Part B - Single Ascending Dose (SAD)
Intervention: Single oral dose of SPT-320 (oprodrug of ...